NCT02555748View on ClinicalTrials.gov

Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

PHASE4CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 17, 2015

Primary Completion Date

January 16, 2020

Study Completion Date

January 16, 2020

Conditions
Metastatic Renal Cell Cancer
Interventions
DRUG

Pazopanib

DRUG

Sunitinib

Trial Locations (8)

12027

CH RODEZ, Rodez

13273

Institut Paoli Calmettes, Marseille

31059

Institut Claudius Regaud, Toulouse

33035

CHU DE BORDEAUX - Hôpital Saint-André, Bordeaux

33076

Institut Bergonie, Bordeaux

34298

Institut Regional Du Cancer Montpellier, Montpellier

69373

Centre Leon Berard, Lyon

87042

CHU DE LIMOGES - Hôpital Dupuytren, Limoges

All Listed Sponsors
collaborator

University Hospital, Bordeaux

OTHER

lead

Institut Claudius Regaud

OTHER

NCT02555748 - Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter